{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T02:52:00Z","timestamp":1720752720685},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Paediatric Respiratory Reviews"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.prrv.2017.08.001","type":"journal-article","created":{"date-parts":[[2017,9,2]],"date-time":"2017-09-02T03:00:23Z","timestamp":1504321223000},"page":"33-36","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Treating resistant Pseudomonas aeruginosa lung disease in young children with cystic fibrosis"],"prefix":"10.1016","volume":"27","author":[{"given":"Sandy Z.P.","family":"Lim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic A.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prrv.2017.08.001_b0005","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1164\/rccm.200304-505SO","article-title":"Pathophysiology and management of pulmonary infections in cystic fibrosis","volume":"168","author":"Gibson","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2017.08.001_b0010","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0966-842X(00)88974-X","article-title":"Pseudomonas aeruginosa, mucoidy and the chronic infection phenotype in cystic fibrosis","volume":"3","author":"Deretic","year":"1995","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.prrv.2017.08.001_b0015","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1128\/MMBR.60.3.539-574.1996","article-title":"Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia","volume":"60","author":"Govan","year":"1996","journal-title":"Microbiol Rev"},{"key":"10.1016\/j.prrv.2017.08.001_b0020","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.tim.2008.12.003","article-title":"Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic fibrosis airways","volume":"17","author":"Hassett","year":"2009","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.prrv.2017.08.001_b0025","unstructured":"Parkins MD, Sibley CD, Elborn JS. Multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis. Part 1: epidemiology, mechanisms, and clinical implications. CML Cystic Fibrosis 2011;1:69\u201376."},{"key":"10.1016\/j.prrv.2017.08.001_b0030","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/BF03256660","article-title":"Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis","volume":"2","author":"Conway","year":"2003","journal-title":"Am J Respir Med"},{"key":"10.1016\/j.prrv.2017.08.001_b0035","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1164\/rccm.201009-1430OC","article-title":"Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections","volume":"183","author":"Mowat","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2017.08.001_b0040","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1073\/pnas.92.7.3019","article-title":"Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface","volume":"92","author":"Imundo","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.prrv.2017.08.001_b0045","doi-asserted-by":"crossref","first-page":"18131","DOI":"10.1073\/pnas.0606428103","article-title":"A physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas aeruginosa biofilms","volume":"103","author":"Matsui","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.prrv.2017.08.001_b0050","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1172\/JCI0213870","article-title":"Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients","volume":"109","author":"Worlitzsch","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.prrv.2017.08.001_b0055","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.tim.2011.04.005","article-title":"Pseudomonas aeruginosa: all roads lead to resistance","volume":"19","author":"Breidenstein","year":"2011","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.prrv.2017.08.001_b0060","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1128\/JB.153.1.281-285.1983","article-title":"Pseudomonas aeruginosa outer membrane permeability: isolation of a porin protein F-deficient mutant","volume":"153","author":"Nicas","year":"1983","journal-title":"J Bacteriol"},{"key":"10.1016\/j.prrv.2017.08.001_b0065","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0140-6736(96)05169-0","article-title":"Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic","volume":"348","author":"Cheng","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.prrv.2017.08.001_b0070","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0954-6111(11)70021-X","article-title":"Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics","volume":"105","author":"Ballmann","year":"2011","journal-title":"Respir Med"},{"key":"10.1016\/j.prrv.2017.08.001_b0075","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1164\/ajrccm\/141.4_Pt_1.914","article-title":"Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone","volume":"141","author":"Regelmann","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.prrv.2017.08.001_b0080","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/0002-9343(89)90040-5","article-title":"Use of ciprofloxacin in cystic fibrosis patients","volume":"87","author":"Bosso","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.prrv.2017.08.001_b0085","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0954-6111(11)70021-X","article-title":"Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics","volume":"105","author":"Ballmann","year":"2011","journal-title":"Resp Med"},{"key":"10.1016\/j.prrv.2017.08.001_b0090","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/thx.2009.121657","article-title":"Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial","volume":"65","author":"Ratjen","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.prrv.2017.08.001_b0095","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2012.06.001","article-title":"Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis","volume":"12","author":"Proesmans","year":"2013","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2017.08.001_b0100","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/(SICI)1099-0496(199705)23:5<330::AID-PPUL4>3.0.CO;2-O","article-title":"Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis","volume":"23","author":"Frederiksen","year":"1997","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.prrv.2017.08.001_b0105","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1164\/rccm.201105-0924OC","article-title":"Fosfomycin\/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection","volume":"185","author":"Trapnell","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2017.08.001_b0110","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1086\/588484","article-title":"Emergence of carbapenem resistance in Pseudomonas aeruginosa isolates from a patient with cystic fibrosis in the absence of carbapenem therapy","volume":"46","author":"Wolter","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.prrv.2017.08.001_b0115","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0272-5231(05)70143-X","article-title":"Antimicrobial resistance in intensive care units","volume":"20","author":"Fridkin","year":"1999","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.prrv.2017.08.001_b0120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1128\/AAC.50.1.43-48.2006","article-title":"Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact","volume":"50","author":"Aloush","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.prrv.2017.08.001_b0125","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/647952","article-title":"Antimicrobial susceptibility testing: a review of general principles and contemporary practices","volume":"49","author":"Reller","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.prrv.2017.08.001_b0130","first-page":"97","article-title":"Multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis. Part 2: management considerations","volume":"1","author":"Parkins","year":"2011","journal-title":"CML Cystic Fibrosis"},{"key":"10.1016\/j.prrv.2017.08.001_b0135","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/jac\/44.3.389","article-title":"Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa","volume":"44","author":"Wu","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.prrv.2017.08.001_b0140","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/clinids\/23.3.532","article-title":"Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation","volume":"23","author":"Saiman","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.prrv.2017.08.001_b0145","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1128\/AAC.39.11.2411","article-title":"Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa","volume":"39","author":"Weiss","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.prrv.2017.08.001_b0150","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1164\/ajrccm.162.6.2005018","article-title":"Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa","volume":"162","author":"Lang","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2017.08.001_b0155","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1164\/rccm.200208-855OC","article-title":"Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis","volume":"167","author":"Gibson","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2017.08.001_b0160","unstructured":"Goldman M, Alcorn M, editors. Prevention of chronic Pseudomonas Aeruginosa colonisation in cystic fibrosis by colistin. In: 18th European Cystic Fibrosis Conference; 1993; Madrid."}],"container-title":["Paediatric Respiratory Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152605421730088X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152605421730088X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T19:18:35Z","timestamp":1602875915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152605421730088X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":32,"alternative-id":["S152605421730088X"],"URL":"https:\/\/doi.org\/10.1016\/j.prrv.2017.08.001","relation":{},"ISSN":["1526-0542"],"issn-type":[{"value":"1526-0542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treating resistant Pseudomonas aeruginosa lung disease in young children with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Paediatric Respiratory Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prrv.2017.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}